Sagimet Biosciences (SGMT) Profit After Tax (2022 - 2026)

Sagimet Biosciences' Profit After Tax history runs 5 years deep, the most recent figure standing at -$10.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 41.14% year-over-year to -$10.8 million in Q1 2026; TTM through Mar 2026 was -$43.6 million, a 23.84% increase from a year earlier, with the FY2025 full-year figure at -$51.1 million, down 12.25% from the prior year.
• Profit After Tax fell to -$10.8 million in Q1 2026 per SGMT's latest filing, from -$9.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$6.4 million in Q3 2023 and bottomed at -$18.3 million in Q1 2025.
• The 5-year median for Profit After Tax is -$8.1 million (2023), against an average of -$9.8 million.
• Across the five-year window, Profit After Tax slumped 175.83% in 2025 and jumped 41.14% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$7.2 million in 2022, then declined by 13.22% to -$8.2 million in 2023, then plunged by 98.76% to -$16.2 million in 2024, then soared by 40.96% to -$9.6 million in 2025, then declined by 12.51% to -$10.8 million in 2026.
• Per Business Quant, the three latest SGMT Profit After Tax figures stand at -$10.8 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.9 million (Q3 2025).